Telo Genomics Corp. (OTCQB: TDSGF), a Vancouver-based biotech specializing in diagnostic and prognostic tests through three-dimensional telomere analysis, announced on November 18, 2026, that it has signed a term sheet dated August 20, 2026. This agreement provides Telo Genomics with an option to obtain an exclusive worldwide commercial license from the University of Manitoba and Technion Research and Development Foundation Ltd. for an artificial intelligence (AI) method and system designed to automatically detect rare malignant cells present at low concentrations in biological samples.
The contemplated license, pending negotiation and execution of a definitive agreement, would grant Telo Genomics exclusive rights to make, use, sell, and import products and processes related to identifying, quantifying, and analyzing cancer cells from human biological samples. These applications include cancer screening, clinical diagnosis, treatment selection, and disease monitoring, encompassing products that may receive regulatory approvals such as FDA, EMA, or Health Canada clearance.
This AI technology is particularly relevant to liquid biopsy minimal residual disease (MRD) testing, where detecting circulating tumor cells at extremely low frequencies is critical. The collaboration aims to integrate the AI method with Telo Genomics’ existing TeloView® platform, which performs single-cell 3D telomere profiling, thereby enabling a more reproducible, scalable, and automated workflow for detecting circulating tumor cells prior to detailed analysis.
John Farlinger, Chief Executive Officer and Chairman of Telo Genomics, described the term sheet as a natural progression of the company’s foundational scientific collaborations. He emphasized that combining highly sensitive detection of circulating tumor cells with AI-driven automation could accelerate workflows and reduce operator variability, enhancing the sensitivity essential for MRD testing. Farlinger noted, "Detecting the right cell is the first step in any liquid-biopsy assay. Automating that step with AI reduces operator variability and supports the sensitivity required for MRD. Pairing automated cell identification with 3D telomere profiling is consistent with our goal of giving clinicians both a count of residual disease and a readout of its biological aggressiveness."
The term sheet covers a worldwide territory and focuses on the field of identifying, quantifying, and analyzing cancer cells from human biological samples. While the option provides a pathway to an exclusive license, no license rights have been granted at this stage. The parties must still negotiate and execute a definitive license agreement, and there is no guarantee such an agreement will be finalized on the proposed terms or at all.
Telo Genomics is recognized for pioneering a comprehensive telomere analysis platform with applications in oncology and neurological diseases. Its liquid biopsy technologies offer less invasive and more reproducible alternatives to traditional diagnostics. The company’s expertise combines quantitative 3D telomere analysis with molecular biology and AI to detect disease-associated genetic instability. Its proprietary technology has been validated in over 190 peer-reviewed publications and 30 clinical studies involving more than 3,000 patients with various cancers and Alzheimer’s disease. The lead product, Telo-MM, targets multiple myeloma, providing actionable clinical information for this aggressive blood cancer.
The University of Manitoba, established in 1877 as Western Canada’s first university, hosts the Max Rady College of Medicine and maintains a broad research portfolio in health sciences and technology translation. Its Partnerships and Knowledge Mobilization office manages commercialization efforts.
Technion Research and Development Foundation Ltd., a subsidiary of the Technion – Israel Institute of Technology, facilitates the commercialization of Technion inventions globally through licensing, startup formation, and industry partnerships. Its technology transfer office, T3, manages the institution’s patent portfolio and sponsored research.
This announcement includes forward-looking statements subject to risks and uncertainties, including the potential failure to finalize the definitive license agreement, the performance of the AI method, and commercialization timelines. Investors and readers are cautioned not to place undue reliance on these statements.
The TSX Venture Exchange and its Regulation Services Provider have not reviewed or accepted responsibility for the adequacy or accuracy of this release.
Telo Genomics Secures Option for Exclusive Global License on AI Technology to Detect Rare Malignant Cells Telo Genomics Corp. has entered into a term sheet granting it an option to exclusively license an AI-based method for automated detection of low-frequency malignant cells. Developed jointly by the University of Manitoba... Read the full IIPLA article: https://iipla.org/news/telo-genomics-secures-option-for-exclusive-global-license-on-ai-technology-to-detect-rare-malignant-cells